Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Temozolomide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.97 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Temozolomide SCHEMBL3739 | 0.98 | MEN1 (1.00) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL3270220 | 0.98 | MEN1 (1.00) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL28275477 | 0.97 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL1534013 | 0.97 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL3784250 | 0.97 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL27721442 | 0.93 | MEN1 (0.89) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL16227379 | 0.89 | MEN1 (0.82) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL10168201 | 0.88 | MEN1 (0.81) | MEN1PABPC1KMT2ACA12CA1 | |
| Altretamine SCHEMBL27875070 | 0.88 | KMT2A (0.80) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL4444959 | 0.87 | MEN1 (0.78) | MEN1PABPC1KMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110177792-B | Process for preparing temozolomide and intermediates | 克里斯泰利亚化学药物产品有限公司 | 2022-03-04 | — | — | CN | claimed |
| US-10865209-B2 | Process for preparing temozolomide and an intermediary | CRISTÁLIA PRODUTOS QUÍMICOS FARMACÊUTICOS LTDA (BR) | 2020-12-15 | — | — | US | claimed |
| US-20200190088-A1 | PROCESS FOR PREPARING TEMOZOLOMIDE AND AN INTERMEDIARY | CRISTÁLIA PRODUTOS QUÍMICOS FARMACÊUTICOS LTDA (BR) | 2020-06-18 | — | — | US | claimed |
| EP-3559001-A1 | PROCESS FOR PREPARING TEMOZOLOMIDE AND AN INTERMEDIARY | Cristália Produtos Químicos Farmacêuticos LTDA (BR) | 2019-10-30 | — | — | EP | claimed |
| WO-2018112589-A1 | PROCESS FOR PREPARING TEMOZOLOMIDE AND AN INTERMEDIARY | CRISTÁLIA PRODUTOS QUÍMICOS FARMACÊUTICOS LTDA (BR) | 2018-06-28 | — | — | WO | claimed |
| WO-2008111092-A1 | CRYSTALLINE TEMOZOLOMIDE MONOHYDRATE AND PROCESS FOR PREPARATION THEREOF | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2008-09-18 | — | — | WO | claimed |
| US-11730732-B2 | Oral suspension of temozolomide | ORPHELIA PHARMA (FR) | 2023-08-22 | — | — | US | disclosed |
| CN-110177792-B | Process for preparing temozolomide and intermediates | 克里斯泰利亚化学药物产品有限公司 | 2022-03-04 | — | — | CN | disclosed |
| EP-3613436-B1 | ORAL SUSPENSION OF TEMOZOLOMIDE | ORPHELIA PHARMA (FR) | 2021-06-02 | — | — | EP | disclosed |
| US-10865209-B2 | Process for preparing temozolomide and an intermediary | CRISTÁLIA PRODUTOS QUÍMICOS FARMACÊUTICOS LTDA (BR) | 2020-12-15 | — | — | US | disclosed |
| EP-3064499-B1 | THE CRYSTALLINE FORMS OF TEMOZOLOMIDE AND THE METHOD FOR PREPARING SAME | JIANGSU TASLY DIYI PHARMACEUTICAL CO LTD (CN) | 2020-07-29 | — | — | EP | disclosed |
| US-20200190088-A1 | PROCESS FOR PREPARING TEMOZOLOMIDE AND AN INTERMEDIARY | CRISTÁLIA PRODUTOS QUÍMICOS FARMACÊUTICOS LTDA (BR) | 2020-06-18 | — | — | US | disclosed |
| US-20200188390-A1 | ORAL SUSPENSION OF TEMOZOLOMIDE | ORPHELIA PHARMA (FR) | 2020-06-18 | — | — | US | disclosed |
| WO-2018112589-A1 | PROCESS FOR PREPARING TEMOZOLOMIDE AND AN INTERMEDIARY | CRISTÁLIA PRODUTOS QUÍMICOS FARMACÊUTICOS LTDA (BR) | 2018-06-28 | — | — | WO | disclosed |
| US-9714250-B2 | Crystalline forms of temozolomide and the method for preparing same | JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) | 2017-07-25 | — | — | US | disclosed |
| US-20160289234-A1 | The Crystalline Forms of Temozolomide and the Method for Preparing Same | JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) | 2016-10-06 | — | — | US | disclosed |
| EP-3064499-A1 | THE CRYSTALLINE FORMS OF TEMOZOLOMIDE AND THE METHOD FOR PREPARING SAME | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (CN) | 2016-09-07 | — | — | EP | disclosed |
| WO-2008111092-A1 | CRYSTALLINE TEMOZOLOMIDE MONOHYDRATE AND PROCESS FOR PREPARATION THEREOF | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008111092-A1 | CRYSTALLINE TEMOZOLOMIDE MONOHYDRATE AND PROCESS FOR PREPARATION THEREOF | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008111092-A1 | CRYSTALLINE TEMOZOLOMIDE MONOHYDRATE AND PROCESS FOR PREPARATION THEREOF | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190088-A1 | PROCESS FOR PREPARING TEMOZOLOMIDE AND AN INTERMEDIARY | ITPA, AMPD1, IDH1 | MEN1 54/4885PABPC1 883/4885KMT2A 32/4885 |
| US-20160289234-A1 | The Crystalline Forms of Temozolomide and the Method for Preparing Same | MGMT, HDHD5, TREH | MEN1 493/4885PABPC1 4067/4885KMT2A 563/4885 |
| US-20200188390-A1 | ORAL SUSPENSION OF TEMOZOLOMIDE | MGMT, TP53, MTDH | MEN1 15/4885PABPC1 2536/4885KMT2A 337/4885 |
| US-11730732-B2 | Oral suspension of temozolomide | MGMT, MTDH, TPMT | MEN1 8/4885PABPC1 2125/4885KMT2A 111/4885 |
| US-10865209-B2 | Process for preparing temozolomide and an intermediary | ITPA, AMPD1, IDH1 | MEN1 54/4885PABPC1 883/4885KMT2A 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.